![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Bentham Science Publishers
E-ISSN: 1873-5576|8|8|647-665
ISSN: 1568-0096
Source: Current Cancer Drug Targets, Vol.8, Iss.8, 2008-12, pp. : 647-665
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
mTOR pathway inhibitors in cancer therapy: moving past rapamycin
Pharmacogenomics, Vol. 11, Iss. 9, 2010-09 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Inhibitors of mTOR pathway for cancer therapy, moving on from rapalogs to TORKinibs
Cancer, Vol. 121, Iss. 19, 2015-10 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
The mTOR Pathway: A New Target in Cancer Therapy
Current Cancer Drug Targets, Vol. 10, Iss. 5, 2010-08 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
mTOR inhibitors in the treatment of cancer
By Fasolo Angelica Sessa Cristiana
Expert Opinion on Investigational Drugs, Vol. 17, Iss. 11, 2008-11 ,pp. :